Calcium-containing restoration materials

Information

  • Patent Grant
  • 8282396
  • Patent Number
    8,282,396
  • Date Filed
    Monday, May 3, 2010
    14 years ago
  • Date Issued
    Tuesday, October 9, 2012
    11 years ago
Abstract
A bone or dental implant material in the form of a paste includes a mixture of calcium phosphate and/or calcium-containing powders, liquid glycerol, organic acid and gelling agent. The paste is stable, resistant to washout and will harden upon exposure to water. Physical characteristics of the paste, including consistency, porosity, and hardening time, are controlled by the choice and ratio of constituents.
Description
BACKGROUND OF THE INVENTION

The various embodiments of the present invention are generally directed to self-hardening calcium phosphate-containing and/or calcium-containing cement compositions. The compositions may be used to form pastes for bone and tooth restoration and similar applications, where the paste will harden within a desired time after being delivered to a repair site.


Most conventional calcium phosphate cements are mixed with an aqueous solution immediately before application. In the clinical situation, the ability of the surgeon to properly mix the cement and then place the cement paste in the defect within the prescribed time is a crucial factor in achieving optimum results


A self-hardening calcium phosphate cement (“CPC”), consisting of tetracalcium phosphate (Ca4(PO4)2O, also referred to as “TTCP”) and dicalcium phosphate anhydrous (CaHPO4, also referred to as “DCPA”), has been shown in clinical studies to be efficacious for repairing bone defects. The hardening time of such conventional cements is as long as about 30 minutes with water, although hardening time can be shortened if a phosphate solution is used as the cement liquid. Hydroxyapatite (Ca5(PO4)3OH, also referred to as “HA”) is formed as the product. More recently, additional CPCs that do not contain TTCP, e.g., α-tricalcium.phosphate (α-Ca3(PO4)2, also referred to as “α-TCP”) and CaCO3 or DCPA and Ca(OH)2, have also been developed. These cements may harden in about 10 minutes when a phosphate solution is used as the cement liquid. They also form hydroxyapatite (“HA”) as the final product.


A premixed CPC paste containing the TTCP and DCPA powders and glycerol as the cement liquid has been used for root canal filling and sealing by injection techniques. The cement paste was found to be stable in a syringe but hardened only after being delivered into the root canal where it became exposed to water from the surrounding tissues. Because the cement paste was injected into a confined area, there was little concern of disintegration of the paste due to washout. Although the premixed CPC was shown to have improved biocompatibility with periapical bone tissue than a number of conventional root canal filling or sealing materials, the premixed CPC-glycerol paste did not exhibit a good washout resistance when it was applied to an open wet field.


There remains a need for premixed cement pastes that are stable in the package, are resistant to washout, and will harden only after being deposited at the site of the defect but, once placed, will then harden within a predetermined time.


BRIEF SUMMARY OF THE INVENTION

The various embodiments of the present invention comprise compositions and means for formulating premixed calcium and/or calcium phosphate and organic acid cement pastes that are stable in a package, resistant to washout, and harden within a desired time after being delivered to the defect or implant site. A non-toxic, non-aqueous, water-miscible liquid such as glycerol is preferred as the liquid in the premix because the cement paste hardening reaction to form calcium complexes and HA does not occur in a water-free environment. An organic acid is used to accelerate cement hardening upon delivery to a desired repair site. Preferred organic acids include carboxylic acids. A gelling agent also may be added to improve the paste cohesiveness.


Methods of repairing and restoring bone and tooth tissue include delivering the pastes to the defect site by any suitable methods known to those of skill in the art. The pastes are exposed to an aqueous fluid to promote hardening of the paste to a cement at a relatively rapid rate.


When premixed self-hardening cements are formulated with sodium phosphate (“Na2HPO4”) to accelerate cement hardening and prepared by mixing glycerol, Na2HPO4, and hydroxypropyl methyl cellulose (“HMC”) with CPC powders, the cements will harden only after being delivered to a desired site. Although Na2HPO4 may serve to accelerate cement hardening, the hardening times (“HT”) of these cements can be 60 minutes or longer. Where shorter hardening times are desired, the present compositions that include organic acids to accelerate cement hardening provide self-hardening calcium phosphate-containing and/or calcium-containing cement pastes having hardening times of about 35 minutes or less.


Thus, it is an object of the invention to provide a premixed composition of a calcium phosphate-containing and/or calcium-containing cement material which exhibits resistance to washout as well as desirable hardening times.


A further object of the invention is to provide an essentially water-free, cement-forming paste capable of forming calcium complexes and HA after exposure to water for repair of dental material and bone.


Another object of the invention is to provide a method for controlling the hardening times of HA forming cements pastes.


Another object of the invention is to provide an HA forming cement formulation capable of remaining in an injectable paste form until exposed to an aqueous environment.


These and other objects, advantages and features of the invention are set forth in the detailed description which follows.







DETAILED DESCRIPTION OF THE INVENTION

Premixed calcium cement pastes for use in bone graft and similar medical repair applications are provided. The pastes may be injectable for delivery to the bone or tooth defect site. The pastes may include a non-toxic, calcium-containing and/or calcium phosphate-containing powder, a non-toxic organic acid capable of forming calcium complexes, and a non-toxic, non-aqueous, water-miscible liquid. Non-aqueous liquids are preferred to limit premature hardening of the pastes, which may harden in aqueous environments. A preferred liquid is glycerin (also sometimes referred to as “glycerol”). The organic acid is used to accelerate the hardening time of the paste upon delivery. Gelling agents, such as HMC, carboxymethyl cellulose (“CMC”), alginate, chitosan, and the like, also can be mixed with the powders to enhance paste cohesiveness and washout resistance.


Because the hardening of these cements results from calcium-complex formation, it is contemplated that self-hardening cements can also be formulated using calcium-containing compounds instead of, or in combination with, calcium phosphate compounds. The calcium phosphate and/or calcium-containing compound powder can include monocalcium phosphate monohydrate (“MCPM”), mono calcium phosphate anhydrous (“MCPA”), dicalcium phosphate anhydrous (“DCPA”), dicalcium.phosphate dehydrate (“DCPD”), octacalcium phosphate (“OCP”), α-TCP, β-tricalcium phosphate (“β-TCP”), amorphous calcium phosphate (“ACP”), calcium deficient HA, non-stoichiometric HA, TTCP, CaSO4, CaSO4.0.5H2O, CaSO4.2H2O, CaO, Ca(OH)2, and CaCO3 and combinations thereof. Preferred calcium phosphate powders include TTCP, DCPA, α-TCP and β-TCP. The Ca/P molar ratio of TTCP is preferably between about 1.67 to about 2, of α-TCP is between about 1.5 to about 1.67, and of β-TCP is between about 1.50 to about 1.67. The particle sizes of the calcium phosphate and/or calcium-containing compounds are between about 1 to about 200 μm and more preferably between about 2 to about 50 μm.


Any suitable, non-toxic, non-aqueous, water-miscible liquid may be used in preparing the pastes. Possible liquids include glycerin, as well as related liquids, such as glycerin compounds, derivatives, substitutes and the like, that are non-toxic, non-aqueous, and water-miscible. Certain alcohols also may be suitable for use as the non-toxic, non-aqueous, water-miscible liquid. Preferably, the liquid is selected from glycerin, propylene glycol, poly(propylene glycol), poly(ethylene glycol), and combinations thereof.


Preferred organic acids are non-toxic, organic carboxylic acids. A number of carboxylic acids form calcium complexes that are not highly soluble. These acids include glycolic, citric, tartaric, malonic, malic, and maleic acids. Some of these acids, when mixed with a powder containing one or more of calcium phosphate compounds and/or calcium-containing compounds produce relatively fast hardening cements. Thus, it is possible that the use of these acids can produce faster setting premixed cements. One or more of these acids are mixed with the powder to provide a stable paste that will harden only upon contact with an aqueous fluid. Without wishing to be bound by any theories, it is believed that the calcium phosphate compounds and/or calcium-containing compounds react with the organic acids in the presence of water to initially form calcium complexes that are not highly soluble, rather than to directly form hydroxyapatite. This then results in more rapid hardening of the paste.


The compositions also may include a non-toxic gelling agent to enhance paste cohesiveness and washout resistance. The gelling agent may include HMC, CMC, chitosan, collagen, gum, gelatin, and alginate, and combinations thereof.


The compositions are prepared and stored under substantially anhydrous conditions to limit premature hardening of the cement pastes. The compositions may be employed as self-hardening cement pastes in a variety of medical and dental procedures for repairing or restoring missing or defective bone or tooth tissue. The cement pastes may be applied to the defect site using any suitable methods, including injecting with a syringe or depositing with a spatula, and also molded or sculpted in vivo as desired. When the cement pastes are exposed to physiologic fluids, which contain water, or another aqueous environment at the defect site, they will harden relatively rapidly. An aqueous fluid may be contacted with the compositions either prior to or after application of the cement pastes at the defect site to enhance the rate of hardening of the cement pastes. As an example, a sodium phosphate or saline solution may be sprayed over the surface of the cement paste after it is delivered to the defect site to promote hardening of the outer surface of the cement paste, which will also assist with maintaining the shape of the cement paste as applied and molded. As another example, water may be mixed with the cement pastes prior to application of the pastes at the defect site to initiate hardening.


For most clinical applications, a cement hardening time of more than 60 minutes is too long. Premixed pastes or self-hardening bone graft pastes (“BGPs”) in accordance with the various embodiments of the present invention will have an HT of no more than about 35 minutes, preferably no more than 20 minutes and even more preferably between about 5 to about 15 minutes.


EXAMPLES

The following examples further illustrate preferred embodiments of the present invention but are not be construed as in any way limiting the scope of the present invention as set forth in the appended claims.


Various premixed self-hardening pastes were prepared. Hardening times and other properties of the pastes were evaluated.


Preparation of the solid ingredients of premixed paste: TTCP was prepared by heating an equimolar mixture of commercially obtained DCPA (Baker Analytical Reagents, J.T. Baker Chemical Co., Phillipsburg, N.J.) and CaCO3 (J.T. Baker Chemical Co.) at 1500° C. for 6 hours in a furnace and quenched at room temperature. The TTCP and DCPA powders of the paste compositions were ground individually in a planetary ball mill in cyclohexane, ethanol, or without a liquid to obtain the desired median particle sizes, which typically is about 15 μm as disclosed in the prior art for making CPC powders. The median particle sizes of TTCP and DCPA were about 17.1 μm and about 1.7 μm, respectively.


α-TCP was prepared by heating a mixture that contained 2 mol of DCPA and 1 mol of CaCO3 to 1500° C. for 6 hours and then quenched in air. The powders were ground individually in a planetary ball mill in cyclohexane, ethanol, or without a liquid to obtain the desired median particle sizes based on data from previous studies. The median particle sizes of α-TCP and CaCO3 were 4.6 and 3.9 μm, respectively. The median particle size of Ca(OH)2 was 2.2 μm. The particle sizes of the components of the pastes prepared in accordance with the present invention generally can be in the range of 1 to 50 μm.


Liquid ingredients of controls and premixed pastes: All ingredients were obtained commercially. A homogeneous mixture of a carboxylic acid, HMC or CMC, and glycerin was produced by blending the mixture in a ball mill.


Preparation of premixed pastes: Premixed paste compositions were prepared by mixing a powder and a liquid at desired powder-to-liquid mass ratios (P/L) on a mixing block until a smooth and homogenous paste was obtained. The compositions, with components expressed in mass fraction (%) are presented in Table 1.












TABLE 1









Liquid
















Carboxylic




Paste
Solid
Glycerin
Acid
Gelling Agent
P/L





P1
TTCP (73%)
62.2%
d-tartaric
HMC (0.3%)
3.0



DCPA (27%)

acid (37.5%)


P2
TTCP (73%)
62.2%
glycolic acid
HMC (0.3%)
3.0



DCPA (27%)

(37.5%)


P3
TTCP (73%)
70.5%
malonic acid
HMC (0.5%)
3.0



DCPA (27%)

(29%)


P4
TTCP (73%)
79.5%
maleic
HMC (0.5%)
3.0



DCPA (27%)

acid (20%)


P5
TTCP (73%)
49.3%
citric
CMC (1.5%)
2.3



DCPA (27%)

acid (49.2%)


P6
TTCP (39.1%)
61.9%
d-tataric acid
CMC (1%)
1.5



α-TCP (60.9%)

(37.1%)


P7
TTCP (55%)
61.9%
d-tataric acid
CMC (1%)
1.5



DCPA (20%)

(37.1%)



α-TCP (25%)


P8
TTCP
61.9%
d-tataric acid
CMC (1%)
1.5





(37.1%)


P9
α-TCP
61.9%
d-tataric acid
CMC (1%)
1.5





(37.1%)









Washout resistance test: The washout resistance of the premixed pastes was tested as follows. Premixed paste samples were shaped into a small sphere by hand, and then placed immediately in a 5 mL of physiologic-like solution (“PLS”) (1.15 mM Ca, 1.2 mM P, 133 mM NaCl, 50 mM HEPES, pH=7.4) at 37° C. The sample was considered to pass the washout resistance test if it did not visibly disintegrate in the PLS. All samples exhibited excellent washout resistance.


Diametral tensile strength (“DTS”) measurement: DTS samples were prepared by placing the premixed paste into a mold (6 mm diameter by 3 mm height) with about 2 MPa of applied pressure. The mold was covered with two fritted glass slides (pore size of about 40 μm to about 60 μm, thickness of about 3.5 mm) and immersed in PLS at 37° C. Glycerol-PLS exchange occurred through the fritted glass, allowing the paste to harden. Samples were removed from molds at about 4 hours, and then each sample was immersed in 30 mL of PLS for an additional 20 hours. In some cases, additional samples were prepared and samples were immersed in PLS for an additional 6 days with the PLS being changed daily (30 mL/specimen at 37° C.) to investigate the effect of PLS immersion on physicochemical properties. DTS values (standard uncertainty equals 5%) were measured on a Universal Testing Machine (United Calibration Corp, Garden Grove, Calif.) using a loading rate of 10 mm/min,


Hardening time measurements: The Gilmore needle method (standard uncertainty equals 5%) was used to measure hardening time on samples prepared as described above for DTS measurements. All samples exhibited short hardening times. The hardening times were as shown in Table 2.












TABLE 2







Premixed
HT (minutes, mean ±



Paste
standard deviation, n = 3)









P1
10 ± 1



P2
15 ± 1



P3
20 ± 1



P4
20 ± 1



P5
35 ± 1



P6
15 ± 1



P7
25 ± 1



P8
35 ± 1



P9
20 ± 1










Assessments of hydroxyapatite formation: Powder X-ray diffraction (“XRD”) analysis was used to estimate the extent of paste conversion to HA. The estimated standard uncertainty in 20 measurements is 0.01° and the minimum mass fraction of a calcium phosphate phase that can be detected by XRD is about 3%.


Diametral Tensile (DTS) Strength


DTS of some of the premixed paste samples were determined as given in Table 3.











TABLE 3





Paste
1-day DTS (MPa)
7-day DTS (MPa)







P1
4.3 ± 0.3 (n = 5)
3.8 ± 0.3


P2
3.1 ± 0.5
3.0 ± 0.3


P3
2.3 ± 0.4
2.7 ± 0.3









Hydroxyapatite (“HA”) Formation: Conversion of the initial cement compositions to HA was incomplete in 1-day samples. Complete and near complete conversion of the initial cement compositions to HA was found in all 7-day samples of premixed pastes using XRD.


In sum, formation of a bone replacement or dental replacement paste results by combining dry powder constituents, characterized by their conversion-to calcium complexes in the presence of carboxylic acids and water. A gelling agent, such as hydroxypropyl methyl cellulose, can be mixed with the powder to improve the cohesiveness of the paste. The ratio of combined constituents is broad and the resulting paste can be formulated to control rather precisely the physical properties of the paste, including injectability, porosity and hardening time.


While particular embodiments of the present invention have been described and illustrated, it should be understood that the invention is not limited thereto as modifications may be made by persons skilled in the art. The present application contemplates any and all modifications that fall within the spirit and scope of the underlying invention disclosed herein.

Claims
  • 1. A method of preparing a paste for bone and tooth restoration, said method comprising the following steps: (a) formulating a composition of components by mixing in a substantially anhydrous condition:(i) a powdered calcium compound in the form of selectively sized powder particles, said particle size in the range of about 1 μm to 50 μm, said particles comprising a calcium compound selected from the group consisting of monocalcium phosphate monohydrate, monocalcium phosphate anhydrous, dicalcium phosphate anhydrous, dicalcium phosphate dehydrate, octacalcium phosphate, a-tricalcium phosphate, B-tricalcium phosphate, amorphous calcium phosphate, calcium deficient hydroxyapatite, non-stoichiometric hydroxyapatite, tetracalcium phosphate, CaSO4, CASO4.0.5H2O, CASO4.2H2O, CaO, Ca(OH)2, CaCO3 and mixtures thereof;(ii) a carboxylic acid for accelerating hardening of said composition when said composition is exposed to water at a delivery site, said acid comprising an acid selected from the group consisting of glycolic, citric, tartaric, malonic, malic, maleic acids and combinations thereof;(ii) a non-toxic, non-aqueous water-miscible liquid; and(iii) a gelling agent; said powder to liquid mass ratio is at least about 1.5, said components blended to obtain a substantially homogeneous formable anhydrous paste mixture having a hardening time of less than about 35 minutes and a diametral tensile strength (DTS) in the range of about 2.7 to 3.8±0.3 MPa within seven days after hardening; and(b) storing said paste mixture under substantially anhydrous conditions.
  • 2. The method of claim 1 wherein the gelling agent is selected from the group consisting of hydroxyl methyl cellulose, carboxymethyl cellulose, chitosan, collagen, gum, gelatin, alginate, and combinations thereof.
  • 3. The method according to claim 1 wherein said miscible liquid is selected from the group consisting of glycerin, propylene glycol, poly(propylene glycol), poly(ethylene glycol) and mixtures thereof.
  • 4. The method of claim 1 wherein the powder particle to liquid mass ratio is in the range of about 1.5 to 3.0.
  • 5. The method of claim 1 wherein said non-toxic, non-aqueous water-miscible liquid is selected from the group consisting of glycerin, propylene glycol, poly (propylene glycol), poly(ethylene glycol) and mixtures thereof; and said gelling agent is selected from the group consisting of hydroxyl methyl cellulose, carboxymethyl cellulose, chitosan, collagen, gum, gelatin, alginate and combinations thereof.
Priority Claims (1)
Number Date Country Kind
PCT/US2004/000742 Mar 2004 WO international
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application based upon and claiming priority to and incorporating by reference Ser. No. 10/552,337 filed Jul. 21, 2006 now U.S. Pat. No. 7,709,029 entitled “Calcium Containing Restoration Materials” which is a U.S. national stage under 35 USC 371 and is a continuation in part of U.S. application Ser. No. 10/057,554, filed Jan. 23, 2002, now U.S. Pat. No. 6,793,725 which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/263,894, filed on Jan. 24, 2001. Ser. No. 10/552,337 also claims the benefit of U.S. Provisional Patent Application Ser. No. 60/461,338, filed on Apr. 8, 2003, all of which are incorporated herein by reference and for which priority is claimed.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This development was supported in part by USPHS, Research Grant DE11789 to the American Dental Association Health Foundation from the NIDCR. The United States or an agency thereof may have certain rights to the claimed invention

US Referenced Citations (73)
Number Name Date Kind
3679360 Rubin et al. Jul 1972 A
3787900 McGee Jan 1974 A
3913229 Driskell et al. Oct 1975 A
3929971 Roy Dec 1975 A
4097935 Jarcho Jul 1978 A
4486403 Mechanic et al. Dec 1984 A
4497075 Niwa et al. Feb 1985 A
4512038 Alexander et al. Apr 1985 A
4518430 Brown et al. May 1985 A
4599085 Riess et al. Jul 1986 A
4612053 Brown et al. Sep 1986 A
4655777 Dunn et al. Apr 1987 A
4813876 Wang Mar 1989 A
4880610 Constantz Nov 1989 A
4897250 Sumita Jan 1990 A
RE33161 Brown et al. Feb 1990 E
4902649 Kimura et al. Feb 1990 A
RE33221 Brown et al. May 1990 E
4963151 Ducheyne et al. Oct 1990 A
5034059 Constantz et al. Jul 1991 A
5037639 Tung Aug 1991 A
5047031 Constantz et al. Sep 1991 A
5053212 Constantz et al. Oct 1991 A
5092888 Iwamoto et al. Mar 1992 A
5129905 Constantz et al. Jul 1992 A
5181930 Dumbleton et al. Jan 1993 A
5192330 Chang et al. Mar 1993 A
5236456 O'Leary et al. Aug 1993 A
5238491 Sugihara et al. Aug 1993 A
5336264 Constanz et al. Aug 1994 A
5455231 Constantz et al. Oct 1995 A
5496399 Ison et al. Mar 1996 A
5508342 Antonucci et al. Apr 1996 A
5522893 Chow et al. Jun 1996 A
5525148 Chow et al. Jun 1996 A
5542973 Chow et al. Aug 1996 A
5545254 Chow et al. Aug 1996 A
5556687 McMillin Sep 1996 A
5652016 Imura et al. Jul 1997 A
5652056 Pepin Jul 1997 A
5695729 Chow et al. Dec 1997 A
5721049 Marcolongo et al. Feb 1998 A
5766618 Laurencin et al. Jun 1998 A
5782971 Constantz et al. Jul 1998 A
5814681 Hino et al. Sep 1998 A
5861445 Xu et al. Jan 1999 A
5962028 Constantz Oct 1999 A
5976234 Chow et al. Nov 1999 A
5997624 Chow et al. Dec 1999 A
6077989 Kandel et al. Jun 2000 A
6136029 Johnson et al. Oct 2000 A
6207098 Nakanishi et al. Mar 2001 B1
6214008 Illi Apr 2001 B1
6281256 Harris et al. Aug 2001 B1
6281257 Ma et al. Aug 2001 B1
6287341 Lee et al. Sep 2001 B1
6325992 Chow et al. Dec 2001 B1
6334775 Xu et al. Jan 2002 B2
6399350 Rubin et al. Jun 2002 B1
6693143 Pflug Feb 2004 B2
6793725 Chow et al. Sep 2004 B2
6949251 Dalal et al. Sep 2005 B2
7018460 Xu et al. Mar 2006 B2
7632878 Xu et al. Dec 2009 B2
7709029 Chow et al. May 2010 B2
20020137812 Chow et al. Sep 2002 A1
20020156152 Zhang et al. Oct 2002 A1
20030147956 Shefer et al. Aug 2003 A1
20030167093 Xu et al. Sep 2003 A1
20030181541 Wu et al. Sep 2003 A1
20040086446 Jia et al. May 2004 A1
20050020720 Dickens et al. Jan 2005 A1
20050260269 Engelbrecht et al. Nov 2005 A1
Foreign Referenced Citations (16)
Number Date Country
4016135 May 1989 DE
0416761 Mar 1991 EP
0520690 Dec 1992 EP
0538913 Apr 1993 EP
0639366 Feb 1995 EP
62275007 Nov 1987 JP
6429266 Jan 1989 JP
1301543 Dec 1989 JP
2311406 Dec 1990 JP
3183605 Aug 1991 JP
3193615 Aug 1991 JP
459611 Feb 1992 JP
408157658 Jun 1996 JP
02311406 Dec 1997 JP
2001170161 Jun 2001 JP
9503369 Jan 1989 WO
Related Publications (1)
Number Date Country
20100212545 A1 Aug 2010 US
Provisional Applications (2)
Number Date Country
60263894 Jan 2001 US
60461338 Apr 2003 US
Divisions (1)
Number Date Country
Parent 10552337 Jul 2006 US
Child 12772843 US
Continuation in Parts (1)
Number Date Country
Parent 10057554 Jan 2002 US
Child 10552337 US